6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer
A systematic review and meta-analysis
Bi-Cheng Wang, MD\textsuperscript{a,\textasteriskcentered} \textsuperscript{a}, Bo-Ya Xiao, MS\textsuperscript{b,\textasteriskcentered} \textsuperscript{c}, Ji-Quan Fan, MD\textsuperscript{a}, Guo-He Lin, MD\textsuperscript{d}, Chang Wang, MD\textsuperscript{e}, Quentin Liu, MD\textsuperscript{f}, Yan-Xia Zhao, MD\textsuperscript{a}

Abstract

Background: Adjuvant trastuzumab improves survival outcomes of human epidermal receptor 2 positive early breast cancer patients. Currently, administration of 12 months adjuvant trastuzumab is the standard therapy. However, whether 6 months treatment is non-inferior to the standard 12 months treatment remains controversial.

Methods: Relevant records were searched in PubMed, Cochrane Library, Web of Science, and EMBASE through Jan 14, 2020. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free survival (DFS) and overall survival (OS) were meta-analyzed. The primary endpoint was DFS with a non-inferiority hazard margin of 1.2 and the second was OS with 1.43.

Results: Three randomized clinical studies met the inclusion criteria, including 3974 patients in 6 months group and 3976 in 12 months group. HR for DFS was 1.18 (95% CI 0.97–1.44, \(P=0.09\)), with the non-inferiority margin comprised in the 95% CI. HR for OS was 1.14 (95% CI 0.98–1.32, \(P=0.08\)), whereas the upper limit of 95% CI did not exceed the non-inferiority hazard margin.

Conclusion: Our analysis failed to show that 6 months treatment was non-inferior to 12 months treatment in improving the DFS. Although the non-inferiority of the 6-month adjuvant trastuzumab treatment was found for OS, considering that breast cancer patients should receive additional systematic therapies when disease progression or relapse happens, we suggest that 12 months adjuvant trastuzumab treatment should remain the standard therapeutic strategy for patients with early human epidermal receptor 2 positive breast cancer.

Abbreviations: CI = confidence interval, DFS = disease-free survival, HER2+ = human epidermal receptor 2 positive, HR = hazard ratio, NCT = National Clinical Trial, OS = overall survival.

Keywords: 6 months, adjuvant, breast cancer, meta-analysis, trastuzumab

Editor: Nazmul Haque.
Ethics approval and consent to participate was not applicable.
Consent for publication: All the authors agree to publish.
Three eligible studies can be downloaded from their official websites or PubMed.
This study was supported by the Hubei Provincial Natural Science Foundation (Grant number: 2020CFB397 to Bi-Cheng Wang), the Independent Innovation Foundation of Wuhan Union Hospital (Grant number: 2019–109 to Bi-Cheng Wang), the Natural Science Foundation of Hubei Province (Grant number: 2019CFB501 to Yan-Xia Zhao), and National Natural Science Foundation of China (Grant number: 81402197 to Yan-Xia Zhao).
The authors have no conflicts of interest to disclose.
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
\textsuperscript{a} Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, \textsuperscript{b} Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, \textsuperscript{c} Department of Medical Psychology, Faculty of Psychology, Naval Medical University (Second Military Medical University), Shanghai, \textsuperscript{d} Department of Oncology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China, \textsuperscript{e} Institute of Anatomy, University of Bern, CH-3012 Bern, Switzerland, \textsuperscript{f} State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, China.
\textsuperscript{\textasteriskcentered}Correspondence: Bi-Cheng Wang, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China (e-mail: bcsnowell@163.com).
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build up the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
How to cite this article: Wang BC, Xiao BY, Fan JQ, Lin GH, Wang C, Lu Q, Zhao YX. 6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: a systematic review and meta-analysis. Medicine 2021;100:10(e24995).
Received: 10 November 2020 / Received in final form: 9 February 2021 / Accepted: 11 February 2021
http://dx.doi.org/10.1097/MD.00000000000024995
**Key points**

1. 6 months trastuzumab treatment was not verified to be non-inferior to 12 months treatment for early HER2+ breast cancer.
2. 12 months adjuvant trastuzumab treatment should be the standard therapeutic strategy for early HER2+ breast cancer.

**1. Introduction**

Administration of 12 months trastuzumab with adjuvant chemotherapy significantly improves the survival outcomes and is the standard-of-care for patients with human epidermal receptor 2 positive (HER2+) operable breast cancer. After a median follow-up of 11 years, the results of HERA study further convinced that 12 months of trastuzumab significantly reduced the risks of disease progression (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.68–0.86) and death (HR 0.74, 95% CI 0.64–0.86) against controlled treatment for HER2+ early breast cancer.

Since the standard therapy has been established, challenges to the 12 months treatment duration for trastuzumab have never stopped. According to HERA study, 2 years of adjuvant trastuzumab had no additional benefit on improving disease-free survival (DFS) compared with standard treatment (HR 1.02, 95% CI 0.89–1.17). In order to reduce cardiac toxicity and cost as well as, convenience to patients, a shorter period of trastuzumab administration, such as 9 weeks, 12 weeks and 6 months, might be an attractive treatment option.

However, the results among these studies vary from each other. Researchers still could not demonstrate the non-inferiority of a shorter duration treatment compared to the standard treatment. Although there are studies showing that 9 weeks trastuzumab adjuvant treatment was not non-inferior to 1 year when patients received similar chemotherapy (DFS: HR 1.39, 90% CI 1.12–1.72), most of them are ongoing trials and the complete results have not been reported.

Among the published studies, PHARE, PERSEPHONE, and HORG deeply compared the efficacy of 6 months trastuzumab adjuvant treatment versus 12 months in HER2+ early breast cancer patients. However, conclusions remain controversial. HORG and PHARE trials failed to show noninferiority for the 6-month trastuzumab treatment, but PERSEPHONE study showed that 6-month treatment was non-inferior to 12-month treatment in HER2+ early breast cancer patients, which is hard for clinicians or patients to make a choice.

Accordingly, we conducted this systematic review and meta-analysis to synthesize the published data and to find whether 6 months treatment of trastuzumab does show non-inferiority versus 12 months treatment.

**2. Methods**

This study was conducted according to the guideline of the Preferred Reporting Items for Systematic Reviews and Meta-analyses. Any disagreements in the process of collecting and analyses were resolved by discussion. The collected published data were not original raw data, therefore, ethical approval was not necessary.

**2.1. Search strategy**

The PubMed, Cochrane Library, Web of Science, and EMBASE online databases were searched to identify relevant articles up to Jan 14, 2020, using the following terms: “breast OR mammary,” “cancer OR tumor OR neoplasm OR adenocarcinoma OR carcinoma,” “6 months OR six months,” “12 months OR twelve months,” and “trastuzumab OR Herceptin.” Reference lists were reviewed and checked for other relevant studies.

**2.2. Study selection**

Two authors (B.W. and G.L.) independently conducted the selection. The inclusion criteria were as follows:

1. studies were prospective randomized clinical trials;
2. patients were diagnosed as early-stage HER2+ breast cancer;
3. 6 months versus 12 months adjuvant trastuzumab treatment;
4. studies were full-text articles and published in English.

For duplicate published trials, the most complete one was eligible.

**2.3. Data extraction**

The following information was collected: name of the first author, name of the study, registered number, year of publication, study design, mean age, median follow-up time, number of patients, and trastuzumab dose. Hazard ratios (HRs) and 95% confidence intervals (CIs) for DFS and overall survival (OS) were extracted for further analyses. This part was performed by B.W. and G.L. independently.

**2.4. Risk of bias assessment**

The Cochrane Risk of Bias Tool in RevMan 5.3 (Cochrane Collaboration’s Information, Management System Nordic Cochrane Centre, Copenhagen, Denmark) was used to evaluate the risk of bias of the selected trials by B.W. and C.W.

**2.5. Statistical analysis**

The primary endpoint was DFS and the second was OS. Adjusted HRs were modified for stratification factors, which were estrogen-receptor status and timing of trastuzumab and chemotherapy. The prespecified non-inferiority margin was set at 3% (PERSEPHONE). The disease progression rate in this study was expected to be 15%, while the mortality was 7%. Thus, the margins converted to HRs of 1.2 [(15 + 3)/15] for DFS and 1.43 [(7 + 3)/7] for OS. Non-inferiority was assumed if the 95% CI did not include the non-inferiority margin. Results were classified as inconclusive if the non-inferiority margin was included in the 95% CI. Treatments were assumed to be inferior if the entire 95% CI exceeded the non-inferiority margin.

Heterogeneity among the studies was calculated by using the $\chi^2$ test. We also quantified the heterogeneity of the results using $I^2$ statistic percentages. A fixed-effects model (Mantel-Haenszel method) was applied if the heterogeneity test showed no statistical significance ($I^2 \leq 50\%$ or $P \geq .10$). Otherwise, a
random-effects model was adopted. RevMan software (version 5.3) was used to calculate the above outcomes.

3. Results

2.6. Search results

Figure 1 displays the selection process. 3712 potential records were searched for the initial assessment. After 865 duplicates were excluded, 2847 records were under further evaluation. 2824 studies were excluded after a review of the titles and abstracts. We then excluded 20 articles, including reviews (n = 1), conference abstracts (n = 14), protocols (n = 2), single-arm studies (n = 1), retrospective studies (n = 1), and duplicated reported trials (n = 1). Finally, three full-text articles met the inclusion criteria. [19–21]

2.7. Study characteristics

Table 1 shows the basic characteristics of the eligible studies. Two trials, PHARE and PERSEPHONE, were published in 2019. HORG trial was published in 2015. All three trials were multicenter studies and had been registered with ClinicalTrials.gov. The mean age ranged from 54 to 56. HORG study had the shortest median follow-up time with 4.3 years in 6 months group

**Table 1**

| First author | Study name | Registered number | Publication year | Design | Mean age (yr) | Median follow-up (yr) | No. patients | Trastuzumab dose |
|--------------|------------|-------------------|------------------|--------|---------------|-----------------------|--------------|-----------------|
| Pivot        | PHARE      | NCT00381901       | 2019             | An open-label, multicenter, randomized, phase 3 trial | 6 mo: 55 | 7.5 | 6 mo: 1693 | Intravenously: 8 mg/kg initial, 6 mg/kg thereafter |
| Earl         | PERSEPHONE | NCT00712140       | 2019             | An open-label, multicenter, randomized, phase 3 trial | 6 mo: 56 | 5.4 | 6 mo: 2044 | Intravenously: 8 mg/kg initial, 6 mg/kg thereafter; subcutaneosly: 600 mg |
| Mavroudis    | HORG      | NCT00615602       | 2015             | An open-label, multicenter, randomized trial | 6 mo: 56 | 4.3 | 6 mo: 240 | Intravenously: 6 mg/kg initial, 4/6 mg/kg thereafter |

NCT = National Clinical Trial.
and 3.9 years in 12 months group. In increasing order, the median follow-up time was 5.4 years in PERSEPHONE study and 7.5 years in PHARE. Trastuzumab was administered by intravenous infusions every 3 weeks (initial dose: 8 mg/kg; thereafter: 6 mg/kg) in PHARE study, delivered every 3 weeks intravenously (initial dose: 8 mg/kg; thereafter: 6 mg/kg) or subcutaneously (600 mg) in PERSEPHONE study, and administered intravenously every 2 weeks starting concurrently with chemotherapy (initial dose: 6 mg/kg; thereafter: 4 mg/kg) and every 3 weeks thereafter (6 mg/kg) in HORG study.

For chemotherapy regimens, patients enrolled in HORG received epirubicin, cyclophosphamide, and 5-fluorouracil every two weeks for four cycles followed by docetaxel every two weeks for four cycles.\(^{[21]}\) While patients who participated in the PHARE and PERSEPHONE studies were treated with four types of chemotherapy regimens, including anthracycline-based, taxane-based, anthracycline-taxane-based, and no taxane/anthracycline chemotherapies.\(^{[19,20]}\)

### 2.8. DFS

Data regarding DFS were available from all selected studies, with 3974 patients in 6 months group and 3976 in 12 months group. The forest plot indicated that 6 months treatment had an 18% higher risk of disease progression compared to the 12 months treatment (adjusted HR 1.18, 95% CI 0.97–1.44, \(P = .09\)) (Fig. 2). The unadjusted HR for DFS is 1.20 (95% CI 0.96–1.48, \(P = .10\)). Both the 95% CIs included the prespecified non-inferiority margin of 1.20.

### 2.9. Overall survival (OS)

OS data were reported in the three clinical trials. In Figure 3, a 14% higher risk of death was displayed when patients were treated with 6 months trastuzumab versus 12 months (adjusted HR 1.14, 95% CI 0.98–1.32, \(P = .08\)). The unadjusted OS data were only available from the PERSEPHONE study, showing that the estimated HR was 1.14 with a 95% CI of 0.92 to 1.42. Accordingly, the prespecified margin of 1.43 was not comprised in the 95% CIs.

### 2.10. Toxicities

In HORG study, researchers found that only two participants (0.8%) in the 6 months group stopped trastuzumab at the early stage of post-chemotherapy due to atrial fibrillation and left ventricular dysfunction and reported no adverse events-related deaths. In the long-term follow-up analysis of PHARE, no difference in the cardiac toxicity between the groups was found. However, the data displayed in the PERSEPHONE were not as positive and optimistic as the other two studies. 11% of patients in 12 months group and 8% in 6 months group experienced clinical cardiac dysfunction. And because of that, 8% of patients in 12 months group and 3% in 6 months group discontinued the administration of trastuzumab in the early stage of adjuvant treatment. Therefore, careful monitoring, including electrocardiograph and ultrasound cardiography, and positive treating the heart dysfunctions (e.g. heart failure and ventricular dysfunction) during the trastuzumab treatment is necessary.

### 2.11. Heterogeneity and risk of bias

Heterogeneities were found in the analyses of DFS but not OS. A random-effect model was used to solve the heterogeneity.

Three studies were all randomized clinical trials and had reported predefined results. Since the selected trials were designed as open-label trials, this analysis should be at a moderate risk of bias for reporting bias (Fig. 4).

### 4. Discussion

The discordant conclusions in studying the 6 months of adjuvant trastuzumab compared to the 12 months of treatment might...
question clinicians to address a therapeutic strategy aimed at reducing treatment duration and confuse patients. The results from PHARE and HORG studies supported the current administration of adjuvant trastuzumab for 12 months, but the PERSEPHONE study provided a positive result to show non-inferiority for 6 months adjuvant trastuzumab treatment.

Therefore, we conducted this study to comprehensively analyze whether 6 months of adjuvant trastuzumab is non-inferior to 12 months in the treatment of early HER2+ breast cancer patients. Data from published clinical trials were extracted and synthesized. According to our analysis, the results were inconclusive regarding the non-inferiority hypothesis of 6 months treatment for DFS (adjusted HR 1.18, 95% CI 0.97–1.44, non-inferiority margin = 1.20).

Across the eligible studies, patients in HORG study only received one chemotherapy regimen, epirubicin, cyclophosphamide, and 5-fluorouracil followed by docetaxel. But HORG study concluded the highest HRs (DFS: 1.58; OS: 1.45). Participants in the other two studies were treated with at least four types of chemotherapy modalities. The effects of different chemotherapies vary from each other. In the subgroup of PERSEPHONE, more patients received taxane-based chemotherapy in 6 months group (13.8% versus 5.5% in 12 months group) and these patients had a higher risk of disease progression or death (DFS: HR 2.47, 95% CI 1.31–4.62; OS: HR 2.62, 95% CI 1.37–5.00). Moreover, age of patients (HR ranged from 0.92 to 1.11), tumor size (HR ranged from 0.94 to 1.10), nodal status (HR ranged from 0.76 to 1.18), and ER status (HR ranged from 0.92 to 1.11) exert impacts on the results. Additionally, stringent criteria for defining the acceptable non-inferiority margin were absent, which played a critical role in the interpretation of the results. The PHARE study used a non-inferiority margin of 2% and set a prespecified HR of 1.15.
PERSEPHONE study, an absolute difference up to 3% was considered acceptable by researchers, with a prespecified HR margin of 1.29. While the HORGH study had an original recruitment target of only 481 patients but with an 8% non-inferiority margin. Different margins are set, the interpretation of the results will be different.

For setting and calculating non-inferiority margins, we found that Darius Soonawala provided a useful method. Like this study, we have chosen 3% as the non-inferiority margin both in DFS and OS. After collecting the original data from the eligible studies, we calculated the rates of disease progression (15%) and mortality (7%) in the 12-months group. Then the margin converted to HRs of 1.2 for DFS and 1.43 for OS. As PERSEPHONE study provided a positive result, we thus set 3% as the margin. With a more stringent margin setting, the more difficult it is to confirm the hypothesis that 6-months of trastuzumab treatment is non-inferior to the standard 12-month treatment. If, in this study, the margin was set at 2%, will our conclusion be different? We have tried and calculated for answering the question. According to Darius Soonawala’s method, the calculated HR margins are 1.13 ([1.5 + 2]/15) for DFS and 1.28 ([1.7 + 2]/7) for OS. Both the 95% CIs include the non-inferiority margin. It’s even harder to indicate the non-inferiority of 6 months of adjuvant trastuzumab versus 12 months of treatment. In addition, owing to the disease progression rate of 15% and the mortality rate of 7%, setting a non-inferiority margin at 8% might not be reasonable.

In addition, non-inferiority regarding OS was found for 6-month adjuvant trastuzumab (adjusted HR 1.14, 95% CI 0.98–1.32, non-inferiority margin = 1.43). Nevertheless, it could not be concluded that 6 months trastuzumab treatment was non-inferior to 12 months treatment, since subsequent-line therapies (e.g. chemotherapy, radiotherapy, endocrine therapy or target-therapy) will be administered after they experience a DFS event.

2.12. Limitation

All enrolled participants were early HER2+ breast cancer patients. As we discussed above, different age, nodal status, tumor size, endocrine receptors status and chemotherapy type might have impacts on the results. Another potentially important factor, Ki-67, has not been shown in these studies. The proliferative index of Ki-67 might exert critical influence in the selection of treatment strategies. Moreover, all the eligible studies were open-label trials, which might partly influence the therapeutic efficacy. Future phase 3 randomized clinical trials in comparing the shorter duration of trastuzumab with 12 months standard of care should be designed as double-blind studies and have more precise subgroup analyses. Additionally, researchers all over the world could reach a consensus on acceptable and reasonable non-inferiority margin in studying the duration of trastuzumab administration. Due to the limited sample, no statistically significant improvement of 6-month trastuzumab treatment compared to standard of care (12 months), but the P values are very close to statistical significance. Further study, like Bayesian network analysis, might help to include more direct and indirect samples in a comprehensive meta-analysis.

5. Conclusion

This systematic review and meta-analysis did not show 6 months trastuzumab adjuvant treatment is non-inferior to 12 months, and 12 months might remain the standard therapeutic strategy for early HER2+ breast cancer patients. Explorations of shorter duration trastuzumab treatment are still meaningful because a cohort of breast cancer patients does benefit from the short duration treatment. Future clinical trials are warranted to confirm the suitable populations.

Acknowledgments

We thank the members of the SNOWELL STUDIO for helping to improve the grammar and spelling.

Author contributions

Study design: B. W. and B. X., data extraction, and data analysis: B. W., G. L. and C. W.; Manuscript writing and edition: B. W., B. X., J. F., Q. L., and Y. Z..

Conceptualization: Bi-Cheng Wang, Bo-Ya Xiao.

Data curation: Bi-Cheng Wang, Guo-He Lin, Chang Wang.

Formal analysis: Bi-Cheng Wang.

Funding acquisition: Bi-Cheng Wang.

Investigation: Bi-Cheng Wang, Guo-He Lin, Chang Wang.

Methodology: Bi-Cheng Wang, Guo-He Lin, Chang Wang.

Project administration: Bi-Cheng Wang.

Resources: Bi-Cheng Wang, Guo-He Lin.

Software: Bi-Cheng Wang, Chang Wang.

Supervision: Bi-Cheng Wang, Quentin Liu, Yan-Xia Zhao.

Validation: Bi-Cheng Wang.

Visualization: Bi-Cheng Wang.

Writing – original draft: Bi-Cheng Wang, Bo-Ya Xiao, Ji-Quan Fan, Quentin Liu.

Writing – review & editing: Bi-Cheng Wang, Bo-Ya Xiao, Ji-Quan Fan, Quentin Liu, Yan-Xia Zhao.

References

[1] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.

[2] Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–83.

[3] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.

[4] Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HER2ceptin (HERA) trial. Lancet Oncology 2017;18(1):1195–205.

[5] Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006;94:828–34.

[6] Scandurra G, Taibi E, Aiello RA, et al. After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting - A single-institution experience. J Clin Oncol 2010;28:

[7] Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncology 2011;12:236–44.

[8] Icli F, Altundag K, Coskun U, et al. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: an observational study of the Turkish Oncology Group. J Clin Oncol 2011;29:

[9] Kizilarslanoglu C, Petekkaya I, Babacan T, et al. Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: a single center experience. J Clin Oncol 2012;30;

[10] Toyali O, Coskun U, Sener N, et al. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. J Cancer Res Clin Oncol 2012;138:2145–51.
[11] Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (London, england) 2013;382:1021–8.

[12] Ghosh J, Joy Phillip DS, Ghosh J, et al. Outcome with use of 12 weeks of adjuvant or neoadjuvant trastuzumab in a resource constrained setting. Cancer Res 2016;76.

[13] Joensuu H, Fraser J, Wildiers H, et al. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study). Cancer Res 2018;78.

[14] Schneider BP, O’Neill A, Shen F, et al. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 2015;113:1631–7.

[15] Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013;14:741–8.

[16] Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: The SOLD randomized clinical trial. JAMA Oncol 2018;4:1199–206.

[17] Niraula S, Gyawali B. Duration of adjuvant trastuzumab in HER-2 positive breast cancer: Pooled results of overall, and disease-free survivals from meta-analyses of randomized controlled trials. Cancer Res 2018;78.

[18] Joensuu H, Fraser J, Wildiers H, et al. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: the SOLD Randomized Clinical Trial. JAMA Oncol 2018;4:1199–206.

[19] Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet (London, england) 2019;393:592–9.

[20] Earl HM, Hiller L, Vallerie AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 14-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019;393:599–612.

[21] Mavroudis D, Saloustros E, Malamos N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 2015;26:1333–40.

[22] Stewart LA, Clarke M, Rovers M, et al. Gron P ID Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313:1657–65.

[23] Soomawala D, Middelburg RA, Egger M, et al. Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. Int J Epidemiol 2010;39:1567–81.

[24] Fushimi A, Tabei I, Fuke A, et al. High-dose toremifene as a promising candidate therapy for hormone receptor-positive metastatic breast cancer with secondary resistance to aromatase inhibitors. Int J Breast Cancer 2020;2020:7156574.

[25] Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020;382:610–21.

[26] Sammons S, Shastry M, Dent S, et al. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR(+) /HER2(-) Breast Cancer. Clin Breast Cancer 2020;20:1–1.

[27] Wikke J, Schick MA, Berger MJ, et al. Progression-free survival for real-world use of palbociclib in hormone receptor-positive metastatic breast cancer. Clin Breast Cancer 2020;20:33–40.

[28] Di Leo A, Jerusalem G, Torres R, et al. First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast 2018;38:144–9.

[29] Sanchez-Munoz A, Navarro-Perez V, Plata-Fernandez Y, et al. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. Clin Breast Cancer 2015;15:343–7.

[30] Bian L, Wang T, Zhang SH, et al. Ki-67 index as a prognostic factor of response and survival for HER2-positive early breast cancer: Pooled results of overall, and disease-free survivals from meta-analyses of randomized controlled trials. Cancer Res 2018;78.

[31] Calhoun BC, Portier B, Wang Z, et al. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. BMC Cancer 2016;16:95.

[32] Min KW, Kim DH, Do SL, et al. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer. Postgrad Med J 2016;92:707–14.

[33] Kurozumi S, Inoue K, Takei H, et al. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer 2015;15:622.

[34] Yamazaki N, Wada N, Yamauchi C, et al. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy. Eur J Surg Oncol 2015;41:617–24.